Michael Rowe
A5033062662- COVID-19 and healthcare impacts
- Prostate Cancer Treatment and Research
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 Clinical Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- Healthcare cost, quality, practices
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Pancreatic and Hepatic Oncology Research
- Body Contouring and Surgery
- Urologic and reproductive health conditions
- Frailty in Older Adults
- Chronic Lymphocytic Leukemia Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Lymphoma Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Traumatic Brain Injury and Neurovascular Disturbances
- Ophthalmology and Visual Impairment Studies
- Multiple and Secondary Primary Cancers
- Patient Safety and Medication Errors
- Fibroblast Growth Factor Research
- Cancer Risks and Factors
Royal Cornwall Hospital
2019-2024
Royal Cornwall Hospital Trust
2022-2024
University Hospitals Plymouth NHS Trust
2021-2023
Janssen (United Kingdom)
2023
Derriford Hospital
2021
National Institute for Biological Standards and Control
2021
St. Vincent Hospital
2016-2020
Alice Springs Hospital
2012
Novartis (United States)
2007
Allergan (United States)
1997
Large cohorts of patients with active cancers and COVID-19 infection are needed to provide evidence the association recent cancer treatment type mortality.
Abstract Background The incidence of cancer diagnosed during pregnancy is increasing. Data relating to investigation and management, as well maternal foetal outcomes lacking in a United Kingdom (UK) population. Methods In this retrospective study we report data from 119 patients with 14 centres the UK across five-year period (2016-2020). Results Median age at diagnosis was 33 years, breast, skin haematological most common primary sites. majority cases were new diagnoses (109 patients,...
The Cancer and Aging Research Group (CARG) score was developed to predict severe chemotherapy-induced toxicity risk in older adults; validation study results have varied. Tolerance of Anti-cancer Systemic Therapy the Elderly sought evaluate CARG prospectively a chemotherapy-naïve UK population. This multicentre, prospective, observational recruited patients aged ≥65 years commencing first-line chemotherapy for any solid organ malignancy or setting. Baseline demographics established frailty...
Cancer patients are at increased risk of death from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). and its treatment affect many haematological biochemical parameters, therefore we analysed these prior to during disease 2019 (COVID-19) correlated them with outcome.
Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, monitoring early intervention critical. We sought to identify features disease in patients predicting build a decision support online tool, Risk Oncology Evaluation Tool (CORONET).
1521 Background: Older adults have a higher risk of developing chemotherapy (CTx) related toxicity. The Cancer Aging Research Group (CARG) score was developed and validated in the USA to predict severe CTx induced toxicity older adults; subsequent validation studies had varying results. TOASTIE study sought evaluate CARG prospectively United Kingdom (UK) population. Methods: This multicentre, prospective, observational recruited patients aged ≥65 years commencing first-line neo-adjuvant,...
Pembrolizumab is an anti-programmed cell death protein 1 immune checkpoint inhibitor with a dosing schedule of 200 mg 3 weekly (q3w). Dose 400 6 (q6w) was approved based on simulation dose/exposure relationships and predicted no difference in toxicity. We present real-world comparative toxicity data. Patients receiving pembrolizumab for any indication between March December 2019 were included across regional centers. Toxicity data collected retrospectively using Common Terminology Criteria...
12026 Background: Immune checkpoint inhibitor (ICI) therapy is now commonly used in a range of tumours and settings. Most data relating to outcomes rates immune-related adverse events (irAE) derived from clinical trial or registry populations small case series. Limited exist for patients aged > 75 years. Here we present multi-centre, real-world analysis the incidence irAEs older adults managed within single comprehensive public health service. We also compare these younger same cohort....
Mondor's disease can manifest itself in the penile dorsal vein. It is a rare complaint with quoted incidence of 1.39%. We report case 41-year-old man who has sex men (MSM), presented swelling and painful erections following intensive vigorous sexual activity. He was found to have thrombosis veins. managed non-steroidal anti-inflammatory drugs abstinence his symptoms resolved two weeks. Practitioners need beware as differential diagnosis presence not underestimate anxiety it cause patient.
Abstract Background Cancer patients are at increased risk of severe COVID-19. As COVID-19 presentation and outcomes heterogeneous in cancer patients, decision-making tools for hospital admission, severity prediction monitoring early intervention critical. Objective To identify features predicting disease build a decision-support online tool; Risk Oncology Evaluation Tool (CORONET) Method Data was obtained consecutive with active laboratory confirmed presenting 12 hospitals throughout the...
Introduction: For patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone (MZL), chemoimmunotherapy (CIT; bendamustine and rituximab [BR] rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone [R-CHOP]) is recommended by international clinical practice guidelines. However, as prognosis remains poor, particularly repeated lines of therapy, there still an unmet need for more effective treatment. The double-blind phase 3 SELENE study evaluated ibrutinib + BR...
Patients with cancer have been shown to increased risk of COVID-19 severity. We previously built and validated the Risk in Oncology Evaluation Tool (CORONET) predict likely severity patients active who present hospital. assessed differences presentation outcomes COVID-19, depending on wave pandemic. examined features at worldwide, waves pandemic: 1 D614G (n = 1430), 2 Alpha 475), 4 Omicron variant 63, UK Spain only). The performance CORONET was evaluated 258, 48, 54 for each wave,...
e15698 Background: Neo-adjuvant approach is emerging as a standard in the management of BR pancreatic cancer patients and various strategies have been described literature. We report our experience with combination nab-Paclitaxel Gemcitabine followed by concurrent Capecitabine radiation therapy patients. . Methods: A prospectively maintained database undergoing neo-adjuvant treatments at center between 01/2013- 6/2015 was reviewed. Pts were treated Gemcitabine(1gm/m2) nab-paclitaxel...
Background: Patients with cancer are at increased risk of severe COVID-19, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction monitoring early intervention critical. We sought to identify features COVID-19 in patients predicting disease build a decision-support online tool; Risk Oncology Evaluation Tool (CORONET).Methods: active (stage I-IV) laboratory confirmed presenting hospitals worldwide were included. Discharge (within...
718 Background: Neo-adjuvant therapy is becoming a preferred approach in the management of BR pancreatic cancer patients. There no consensus on an ideal treatment regimen. We report our experience with combination nab-Paclitaxel/Gemcitabine followed by concurrent Capecitabine and radiation treatments Methods: A prospectively maintained database patients undergoing neo-adjuvant at center between 01/2013- 11/2017 was reviewed. Patients were treated Gemcitabine(1gm/m2) nab-paclitaxel (125mg/m2)...
81 Background: Intermittent hormone manipulation in castrate-sensitive prostate cancer can improve quality of life whilst maintaining comparable disease outcomes with continuous scheduling. Enzalutamide is effective metastatic castrate-resistant (mCRPC) treatment but have significant side-effects. We conducted a retrospective analysis patients treated intermittent enzalutamide compared dosing. Methods: Patients prescribed for mCRPC at Royal Cornwall Hospital from September 2011 to February...
Background: We investigated our institution’s mCRPC enzalutamide or abiraterone patients examining PSA responses and impact of sequencing these drugs. Methods: All / (2011-2018) were included. Rates >50% response (PSA50) compared. Time to treatment failure (TTF) overall survival (OS) was analysed as per lines previous therapy timing chemotherapy. Results: 363 included (Enza n=236, Abi n=127), with 15.6 months median follow-up. PSA50 greater in group (58% vs 31% p<0.0005) but TTF...